Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Maney, Sathish Kumar
Münch, Philipp C
McHardy, Alice C
Lang, Philipp A
Hoell, Jessica I
MetadataShow full item record
AbstractThe RNA-binding protein Musashi 2 (MSI2) has emerged as an important regulator in cancer initiation, progression, and drug resistance. Translocations and deregulation of the MSI2 gene are diagnostic of certain cancers, including chronic myeloid leukemia (CML) with translocation t(7;17), acute myeloid leukemia (AML) with translocation t(10;17), and some cases of B-precursor acute lymphoblastic leukemia (pB-ALL). To better understand the function of MSI2 in leukemia, the mRNA targets that are bound and regulated by MSI2 and their MSI2-binding motifs need to be identified. To this end, using photoactivatable ribonucleoside cross-linking and immunoprecipitation (PAR-CLIP) and the multiple EM for motif elicitation (MEME) analysis tool, here we identified MSI2's mRNA targets and the consensus RNA-recognition element (RRE) motif recognized by MSI2 (UUAG). Of note, MSI2 knockdown altered the expression of several genes with roles in eukaryotic initiation factor 2 (eIF2), hepatocyte growth factor (HGF), and epidermal growth factor (EGF) signaling pathways. We also show that MSI2 regulates classic interleukin-6 (IL-6) signaling by promoting the degradation of the mRNA of IL-6 signal transducer (IL6ST or GP130), which, in turn, affected the phosphorylation statuses of signal transducer and activator of transcription 3 (STAT3) and the mitogen-activated protein kinase ERK. In summary, we have identified multiple MSI2-regulated mRNAs and provided evidence that MSI2 controls IL6ST activity that control oncogenic signaling networks. Our findings may help inform strategies for unraveling the role of MSI2 in leukemia to pave the way for the development of targeted therapies.
CitationJ Biol Chem. 2018;293(40):15359-15369. doi:10.1074/jbc.RA118.002243.
AffiliationBRICS, Braunschweiger Zentrum für Systembiologie, Rebenring 56,38106 Braunschweig, Germany.
PubMed Central IDPMC6177596
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Genome-wide analysis of Musashi-2 targets reveals novel functions in governing epithelial cell migration.
- Authors: Bennett CG, Riemondy K, Chapnick DA, Bunker E, Liu X, Kuersten S, Yi R
- Issue date: 2016 May 5
- p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation.
- Authors: Fahmi A, Smart N, Punn A, Jabr R, Marber M, Heads R
- Issue date: 2013 Apr
- Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
- Authors: Zhang H, Tan S, Wang J, Chen S, Quan J, Xian J, Zhang Ss, He J, Zhang L
- Issue date: 2014 Jan 1
- Control of gp130 expression by the mitogen-activated protein kinase ERK2.
- Authors: Bonito NA, Drechsler J, Stoecker S, Carmo CR, Seckl MJ, Hermanns HM, Costa-Pereira AP
- Issue date: 2014 Apr 24
- HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells.
- Authors: Nguyen DTT, Lu Y, Chu KL, Yang X, Park SM, Choo ZN, Chin CR, Prieto C, Schurer A, Barin E, Savino AM, Gourkanti S, Patel P, Vu LP, Leslie CS, Kharas MG
- Issue date: 2020 Apr 24